相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer
Baptiste Kas et al.
JAMA ONCOLOGY (2020)
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
Jacob J. Adashek et al.
TRENDS IN CANCER (2020)
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities
Yada Kanjanapan et al.
CANCER (2019)
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Giuseppe Lo Russo et al.
CLINICAL CANCER RESEARCH (2019)
Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series
Daniel Jiahao Wong et al.
IMMUNOTHERAPY (2019)
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report
Ilke Tunali et al.
LUNG CANCER (2019)
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentrereal- world cohort
Bernhard Scheiner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
C. G. Kim et al.
ANNALS OF ONCOLOGY (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
Motoko Tachihara et al.
JOURNAL OF THORACIC DISEASE (2019)
Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
Zhi Ji et al.
BMC CANCER (2019)
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Youjin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
Jong Yeob Kim et al.
CANCERS (2019)
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
Akinori Sasaki et al.
GASTRIC CANCER (2019)
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara et al.
JAMA ONCOLOGY (2018)
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Stephane Champiat et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Stephane Champiat et al.
CLINICAL CANCER RESEARCH (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials
Dickran Kazandjian et al.
SEMINARS IN ONCOLOGY (2017)
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E. Saada-Bouzid et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
Yijiu Ren et al.
ONCOTARGET (2016)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)